Moskvin Sergey, Askhadulin Evgeniy, Kochetkov Andrey
O.K. Skobelkin State Scientific Center of Laser Medicine Under the Federal Medical Biological Agency, Studencheskaya str., 40, Moscow 121165, Russia.
Center for the Treatment of Patients with COVID-19, "Outpatient Clinic of Rassvet Settlement", Rassvet settlement, 38, Tula 301212, Russia.
Rehabil Res Pract. 2021 Jan 26;2021:6626932. doi: 10.1155/2021/6626932. eCollection 2021.
The aim of the article is to justify the application of low-level laser therapy (LLLT) to prevent the development of endothelial dysfunction in COVID-19 patients. The results of treating and rehabilitating patients with COVID-19 and prevention of the disease using low-level laser therapy (LLLT) are evaluated.
A literature review is conducted on mechanisms of vascular homeostasis regulation, biomodulating effect of laser light, and LLLT methods for preventing endothelial dysfunction. A total of 106 patients were treated in two COVID-19 healthcare centers in Russia. 22 patients with SARS (+) pneumonia at the stage of resolving the pathological lesion were admitted to rehabilitation using pulsed IR laser. 14 patients with acute forms of COVID-19 were treated using LASMIK device: wavelength 904 nm, pulsed mode, externally and ILBI-525 (intravenous laser blood illumination) + LUVBI (ultraviolet laser blood illumination). 70 persons underwent preventive courses of noninvasive LLLT.
It was shown that LLLT is effective in preventing the development of endothelial dysfunction. Clinical experience demonstrated good tolerability of the treatment, improvement in sputum discharge, and an improvement in overall health. The severity of general hypoxia decreased by the 5th procedure. The procedures for prevention of the disease were well tolerated; there were no cases of COVID-19.
Low-level laser therapy is a justified treatment method that promotes lung tissue regeneration and mitigates the consequences of the disease. The obtained results confirm that LLLT can be used for the effective prevention and treatment of COVID-19 patients.
本文旨在论证低强度激光疗法(LLLT)在预防新冠病毒病(COVID-19)患者内皮功能障碍发展方面的应用合理性。评估了使用低强度激光疗法(LLLT)治疗和康复COVID-19患者以及预防该疾病的效果。
对血管稳态调节机制、激光的生物调节作用以及预防内皮功能障碍的低强度激光疗法进行文献综述。俄罗斯的两个COVID-19医疗中心共治疗了106例患者。22例处于病理病变消退阶段的严重急性呼吸综合征(SARS)(+)肺炎患者采用脉冲红外激光进行康复治疗。14例COVID-19急性发病患者使用LASMIK设备进行治疗:波长904 nm,脉冲模式,体外照射以及采用ILBI-525(静脉激光血液照射)+LUVBI(紫外线激光血液照射)。70人接受了非侵入性低强度激光疗法的预防疗程。
结果表明,低强度激光疗法在预防内皮功能障碍发展方面有效。临床经验表明该治疗耐受性良好,痰液排出改善,整体健康状况得到改善。到第5次治疗时,全身缺氧的严重程度有所降低。疾病预防疗程耐受性良好;未出现COVID-19病例。
低强度激光疗法是一种合理的治疗方法,可促进肺组织再生并减轻疾病后果。所得结果证实,低强度激光疗法可用于有效预防和治疗COVID-19患者。